Lung Cancer Stage Four 10 Years Cancer-Free Through Immunotherapy

Recurrent lung cancer responds to Integrative Immunotherapy

News provided by

Dec 19, 2013, 04:15 ET

SCOTTSDALE, Ariz., Dec. 19, 2013 /PRNewswire/ -- Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/64826-issels-recurrent-lung-cancer-responds-to-integrative-immunotherapy

Since 2010 Immunotherapy with the Dendritic Cell Vaccine has been FDA-approved for prostate cancer, and for other cancer types it is only available in the US in trial studies.

However, for over 10 years cancer patients have had the option to receive Dendritic Cell Vaccine as part of the Issels Integrative Immunotherapy in Tijuana, Mexico, where it is approved.

Jim Gibson, a patient who underwent the Issels Integrative Immunotherapy in 2003 for his recurrent small cell lung cancer – one of the most lethal forms of cancer - achieved documented complete remission. Jim has been cancer-free for the past decade and leads an active life. He shares his experience on his website www.survivingsmallcell.com.

Please see the video of Jim Gibson on the top right of the Multimedia News Release.

Issels Integrative Immunotherapy distinguishes itself decisively from the mere administration of a vaccine. The Issels strategy integrates specific autologous cancer vaccines, such as the Dendritic Cell Vaccine, as well as autologous Lymphokine-Activated Killer (LAK) Cells and activated autologous Natural Killer (NK) Cells, which work on the cell-mediated level of the immune system, into a comprehensive immunobiologic core treatment. This core treatment addresses the tumor microenvironment and herewith the various other levels of the body's complex defense mechanisms, enhancing the efficacy of the vaccine and cell therapies.

Issels Integrative Immunotherapy is a highly specialized non-toxic treatment and always personalized according to each patient's needs. It is based on, and an expansion of, the integrative cancer treatment strategy developed by Dr. Josef M. Issels, MD.

In 1951, Dr. Issels founded the world's first hospital specializing in integrative cancer treatment introducing integrative immunotherapy as a fourth weapon against cancer. Ninety percent of his patients had failed standard treatments and yet a remarkable number achieved documented complete long-term tumor remissions and remained cancer-free for many years or decades.

The very experienced Issels medical team in Tijuana, Mexico has been providing individualized integrative immunotherapy at the most modern hospital of the largest private hospital network of 22 hospitals in Mexico. The hospital meets the highest US and international standards of patient care and safety, and is the only full-service hospital in Mexico offering integrative medicine, including specialized standard treatment protocols, if needed and still possible.

The Issels immunobiologic core treatment is available at the Issels US out-patient facility, where patients can also receive genetically-tested advanced targeted cancer therapies. Notably, a patient with thyroid, bladder and prostate cancer with bone metastases has shown remarkable results from this comprehensive core treatment program.

Please see the video of Roderick Stephen on the top right of the Multimedia News Release.

For more information visit the Issels website at www.issels.com and learn more about the treatment programs and facilities, or watch more videos of patient testimonials.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/64826-issels-recurrent-lung-cancer-responds-to-integrative-immunotherapy

SOURCE Issels Foundation